Red wine and red wine polyphenolic compounds but not alcohol inhibit ADP-induced platelet aggregation

D.W. De Lange1, P.H. Van Golden, W.L.G. Scholman

  • 1Department of Internal Medicine, Meander Medical Center, PO Box 1502, 3800 BM Amersfoort, The Netherlands.

Insights

Red wine polyphenols, not alcohol, inhibit platelet aggregation. This effect, seen only at very high red wine concentrations, may not be clinically relevant for moderate drinkers.

Area of Science:

  • Cardiovascular Health
  • Pharmacology
  • Nutrition Science

Background:

  • Moderate alcohol intake is linked to reduced cardiovascular disease (CVD) risk, particularly coronary heart disease (CHD).
  • Red wine's polyphenols are hypothesized to offer superior cardioprotection compared to other alcoholic beverages.
  • Inhibition of platelet aggregation is a potential mechanism for red wine's cardiovascular benefits.

Purpose of the Study:

  • To investigate the direct impact of alcohol and red wine polyphenols on platelet aggregation.
  • To differentiate the effects of alcohol versus polyphenolic compounds in red wine on platelet function.

Main Methods:

  • Blood platelets were treated with varying concentrations of red wine, red wine polyphenolic extract, or alcohol.
  • Platelet aggregation was induced using adenosine diphosphate (ADP) and measured using an aggregometer.
  • Results were compared against a control group treated with a saline solution.

Main Results:

  • Alcohol, up to 0.24% concentration, showed no significant inhibition of ADP-induced platelet aggregation in vitro.
  • Red wine polyphenolic extract demonstrated a dose-dependent and significant inhibition of platelet aggregation.
  • Red wine itself only inhibited platelet aggregation at very high concentrations (0.24% and 0.48% alcohol).

Conclusions:

  • The inhibitory effect of red wine on platelet aggregation is attributed to its polyphenolic compounds, not alcohol.
  • Alcohol lacks a direct inhibitory effect on platelet aggregation within the tested concentrations.
  • The observed effects at high concentrations suggest limited clinical relevance for moderate red wine consumption regarding direct platelet inhibition.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...